Unknown

Dataset Information

Postdose 3 G1 serum neutralizing antibody as correlate of protection for pentavalent rotavirus vaccine.


ABSTRACT: Although clinical trials of the pentavalent rotavirus vaccine (RotaTeq®, RV5) have demonstrated efficacy against RV gastroenteritis (RGE) in low and high-income settings, a clear correlate of protection or a measure of immune response that could predict efficacy has yet to be identified. This is the first time that immunogenicity data with both serum neutralized antibody (SNA) titers and anti-RV IgA titers from several clinical efficacy trials were pooled to provide a unique context for evaluating the correlation between immunogenicity and RGE risk or efficacy of RV5. The correlation between immunogenicity and RGE risk is evaluated with data at the individual subject level. The analyses show that higher Postdose 3 (PD3) G1 SNA titers are associated with lower odds of contracting any RGE. T

SUBMITTER: Liu GF 

PROVIDER: S-EPMC5647971 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature